The study of PD-1/PD-L1 inhibitors in the treatment of glioma must overcome numerous challenges, because glioma is a highly heterogeneous tumor, with PD-1/PD-L1 expression levels, immune cell composition, and response to treatment varying among different patients. This evidence concerns the gene CD274 and central nervous system cancer.